Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery.

CONCLUSIONS: Apixaban is more cost-effective than enoxaparin for the prevention of postoperative VTE in patients with gynecologic cancer. This appears to be driven largely by DVT and CRNMB prevention.
PMID: 32854972 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - August 23, 2020 Category: Cancer & Oncology Authors: Glickman A, Brennecke A, Tayebnejad A, Matsuo K, Guntupalli SR, Sheeder J Tags: Gynecol Oncol Source Type: research